SASH3 and cancer: Additionally, we conducted a correlation analysis between SASH3 expression and IC50 of 192 anticancer drugs and discovered that patients with low SASH3 expression might be resistant to most anti-cancer drugs, such as I-BET-762, IK-93, PCA-1, A-793887, NPK76-II-72-1, Methotrexate, NG-25, KIN001-102, BX-912, CAL-101, XMD13-2, AT-7519, and Tubastatin A.